OECKL, P., S. HALBGEBAUER, S. ANDERL-STRAUB, CAF. VON ARNIM, J. DIEHL-SCHMID, L. FROELICH, T. GRIMMER, L. HAUSNER, J. DENK, H. JAHN, P. STEINACKER, JH. WEISHAUPT, AC. LUDOLPH a M. OTTO. Targeted Mass Spectrometry Suggests Beta-Synuclein as Synaptic Blood Marker in Alzheimer's Disease. Journal of Proteome Research. Washington, USA: AMER CHEMICAL SOC, 2020, roč. 19, č. 3, s. 1310-1318. ISSN 1535-3893. Dostupné z: https://dx.doi.org/10.1021/acs.jproteome.9b00824. |
Další formáty:
BibTeX
LaTeX
RIS
@article{1833139, author = {Oeckl, P. and Halbgebauer, S. and AnderlandStraub, S. and von Arnim, CAF. and DiehlandSchmid, J. and Froelich, L. and Grimmer, T. and Hausner, L. and Denk, J. and Jahn, H. and Steinacker, P. and Weishaupt, JH. and Ludolph, AC. and Otto, M.}, article_location = {Washington, USA}, article_number = {3}, doi = {http://dx.doi.org/10.1021/acs.jproteome.9b00824}, keywords = {Alzheimer's disease; beta-synuclein; Creutzfeldt-Jakob disease; mass spectrometry; synaptic blood biomarker; MRM; cerebrospinal fluid; dementia}, language = {eng}, issn = {1535-3893}, journal = {Journal of Proteome Research}, note = {FairPark II}, title = {Targeted Mass Spectrometry Suggests Beta-Synuclein as Synaptic Blood Marker in Alzheimer's Disease}, url = {https://pubs.acs.org/doi/10.1021/acs.jproteome.9b00824}, volume = {19}, year = {2020} }
TY - JOUR ID - 1833139 AU - Oeckl, P. - Halbgebauer, S. - Anderl-Straub, S. - von Arnim, CAF. - Diehl-Schmid, J. - Froelich, L. - Grimmer, T. - Hausner, L. - Denk, J. - Jahn, H. - Steinacker, P. - Weishaupt, JH. - Ludolph, AC. - Otto, M. PY - 2020 TI - Targeted Mass Spectrometry Suggests Beta-Synuclein as Synaptic Blood Marker in Alzheimer's Disease JF - Journal of Proteome Research VL - 19 IS - 3 SP - 1310-1318 EP - 1310-1318 PB - AMER CHEMICAL SOC SN - 15353893 N1 - FairPark II KW - Alzheimer's disease KW - beta-synuclein KW - Creutzfeldt-Jakob disease KW - mass spectrometry KW - synaptic blood biomarker KW - MRM KW - cerebrospinal fluid KW - dementia UR - https://pubs.acs.org/doi/10.1021/acs.jproteome.9b00824 N2 - Synaptic degeneration is a major hallmark of Alzheimers disease (AD) and the best pathological correlate of cognitive dysfunction. Synaptic markers are therefore a highly desired read-out for patient diagnosis and possible follow-up in clinical trials. Several synaptic markers for AD are described in cerebrospinal fluid (CSF), but studies in blood have failed so far. Using quantitative mass spectrometry (IP-MS, MRM) we observed increased concentrations of the presynaptic protein beta-synuclein (beta Syn) in CSF and blood of AD patients (n = 64, p < 0.01) and confirmed this finding in two validation cohorts (AD: n = 40 and n = 49, controls: n = 44 and n = 25). beta Syn was already increased in patients with mild cognitive impairment (p < 0.01) and was also markedly increased in Creutzfeldt-Jakob disease (CJD; n = 25, p < 0.001) but not behavioral variant frontotemporal dementia (n = 16), dementia with Lewy bodies/Parkinsons disease dementia (n = 13), Parkinsons disease (n = 25), or amyotrophic lateral sclerosis (n = 30). The diagnostic sensitivity and specificity for CJD versus other neurodegenerative diseases was >= 96%. These findings suggest beta Syn as a candidate blood marker for synaptic degeneration that might be used in clinical AD trials and patient follow-up as part of the recently suggested ATN biomarker panel. It can also serve in the differential diagnosis of CJD. ER -
OECKL, P., S. HALBGEBAUER, S. ANDERL-STRAUB, CAF. VON ARNIM, J. DIEHL-SCHMID, L. FROELICH, T. GRIMMER, L. HAUSNER, J. DENK, H. JAHN, P. STEINACKER, JH. WEISHAUPT, AC. LUDOLPH a M. OTTO. Targeted Mass Spectrometry Suggests Beta-Synuclein as Synaptic Blood Marker in Alzheimer's Disease. \textit{Journal of Proteome Research}. Washington, USA: AMER CHEMICAL SOC, 2020, roč.~19, č.~3, s.~1310-1318. ISSN~1535-3893. Dostupné z: https://dx.doi.org/10.1021/acs.jproteome.9b00824.
|